Tremfya

Tremfya

guselkumab

Manufacturer:

Janssen

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Guselkumab
Indications/Uses
Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Active psoriatic arthritis in adult patients who have had inadequate response or who have been intolerant to prior DMARD therapy. Moderate to severe palmoplantar pustulosis (PPP) in adult patients who do not adequately respond to conventional therapy.
Dosage/Direction for Use
100 mg SC inj at wk 0 & 4, then every 8 wk thereafter.
Contraindications
Special Precautions
Infections, do not initiate in patients w/ any clinically important active infection. Pre-treatment evaluation for TB. Immunizations, to complete all age appropriate immunizations prior to initiating therapy. Hypersensitivity reactions. Hepatic transaminase elevations, to evaluate liver enzymes at baseline & thereafter according to routine patient management.
Adverse Reactions
Resp tract infections. Increased transaminases. Headache. Diarrhoea. Arthralgia. Inj site erythema.
Drug Interactions
CYP450 substrate. Not to be given concurrently w/ live vaccines.
MIMS Class
Immunosuppressants / Psoriasis, Seborrhea & Ichthyosis Preparations
ATC Classification
L04AC16 - guselkumab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.
Presentation/Packing
Form
Tremfya soln for inj (pre-filled syringe) 100 mg/mL
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in